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Abstract
Background Appetite-regulating hormones seem to play an
important role in weight loss after bariatric surgery. Less is
known regarding long-term weight loss maintenance. The
objective of the study was to evaluate ghrelin and obestatin
levels following long-term weight loss achieved through
bariatric surgery or a lifestyle intervention in morbidly
obese patients.
Methods The study was cross-sectional in design carried
out in a university research center setting. The participants
were weight-stable morbidly obese patients who had
undergone, on average, 3 years ago, Roux-en-Y gastric
bypass (RYGB) surgery (n=9) or a lifestyle weight loss
intervention (n=8), and patients on a waiting list for
bariatric surgery (control group; n=9). The main outcome
measures were fasting/postprandial plasma levels of total
ghrelin and obestatin and ghrelin/obestatin ratio.
Results Fasting ghrelin and obestatin plasma levels were
significantly elevated in the RYGB, but not in the lifestyle
group, as compared with the control group. There was no
statistical significant difference in fasting ghrelin/obestatin
ratio among study groups. Ghrelin levels were suppressed
after breakfast in all groups, with no significant differences
in postprandial levels overtime between them. Obestatin
levels did not change postprandially in any of the groups,
but the area under the curve was significantly higher in the
RYGB than in the control group.
Conclusions Sustained weight loss maintenance seems to
be associated with increased fasting levels of ghrelin and
obestatin after RYGB surgery, but not after a lifestyle
intervention, while maintaining ghrelin/obestatin ratio.
Ghrelin is, therefore, unlikely to contribute to weight loss
maintenance after RYGB, and other mechanisms are
probably involved.
Keywords Weight loss maintenance.Bariatric surgery.
Lifestyle intervention.Ghrelin.Obestatin
Introduction
The impact of weight loss achieved through Roux-en-Y
gastric bypass (RYGB) on the plasma levels of ghrelin, the
only peripheral hormone with orexigenic properties (i.e.,
having a stimulating effect on appetite) [1], remains a
matter of continued debate. Cummings and colleagues [2]
in 2002 were the first to report reduced ghrelin levels in
patients who had undergone RYGB, compared with
normal-weight and obese matched controls. This was a
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ghrelin secretion, while conventional methods of weight
loss involving diet and exercise induced the opposite
response [2–4]. This could contribute to the long-term
weight loss maintenance observed with this bariatric
procedure as compared with lifestyle interventions. How-
ever, subsequent studies have produced controversial
results, with some reporting a significant reduction [5–8];
others, no change [9, 10]; and others, an increase in fasting
ghrelin plasma levels after RYGB [11, 12]. The status of
energy balance (whether patients are in active weight
loss or have achieved a stable lower body weight) could
be a factor modulating ghrelin plasma levels after
RYGB. Ghrelin plasma levels were reported to increase
after RYGB in those undergoing active weight loss, but
reported not to change in those who were weight-stable,
despite a similar degree of weight loss [13]. However,
other studies have shown that, despite patients actively
losing weight 6 months after RYGB, their ghrelin plasma
levels were significantly reduced compared with pre-
operative levels [5, 6]. Overall, it remains unknown if
long-term weight loss maintenance in morbidly obese
patients after RYGB or a lifestyle intervention has any
impact on ghrelin secretion.
Obestatin is a recently discovered 23-amino acid
peptide encoded by the ghrelin gene [14]. Although in
the original work of Zhang et al. [14] obestatin has been
shown to suppress food intake and decrease gastric
emptying, therefore antagonizing the orexigenic effect of
ghrelin, subsequent studies in rodents have yielded contro-
versial results [15–17]. In view of this controversy, it is
important to understand how changes in energy balance
affect obestatin plasma levels in humans. The majority [18–
20], but not all studies [21], show that fasting obestatin
plasma levels are reduced in obese compared with normal-
weight individuals, therefore, supporting a role for
obestatin in the regulation of body weight and energy
homeostasis. Ghrelin/obestatin ratio has also been de-
scribed to be reduced in obese women compared with
normal-weight controls [21]. In contrast to the large
number of studies on the impact of RYGB on ghrelin
plasma levels, only one study has assessed the potential
effects of this bariatric procedure on obestatin levels,
reporting no change postoperatively at 2 years and a
significant reduction in ghrelin/obestatin ratio [8]. To our
knowledge, only two studies have looked at the impact of
weight loss achieved through conservative means on
obestatin plasma levels and they were both in children
[22, 23]. The aim of this study was, therefore, to
determine the impact of sustained weight loss 3 years
after RYGB or a lifestyle intervention on the fasting and
postprandial plasma levels of ghrelin and obestatin and
ghrelin/obestatin ratio in morbidly obese patients.
Subjects and Methods
Participants
Three groups of adult patients were recruited to participate
in this study: (1) morbidly obese patients who had
undergone, on average, 3 years before, RYGB surgery (n=
9); (2) or a lifestyle weight loss intervention (n=8); and (3)
morbid obese patients on waiting list for bariatric surgery
(n=9). We used the records from our center to identify the
potential candidates, who were later contacted and invited to
participate. The interval between intervention and metabolic
evaluation was 36±4 months for the RYGB group and 32±
10 months for the lifestyle group. The exclusion criteria
included pregnancy, enrolment in another obesity treatment,
previous bariatric surgery, drug or alcohol abuse, and mental
disorders and/or physical impairment which could interfere
with the ability to comply with treatment. All the subjects
were white Caucasian and with ages ranging from 25 to
61 years. Patients in all three groups had stable weight at the
time of the evaluation, as defined by a change of no more
than 5% in body weight during the preceding 3 months. Pre-
intervention excess weight (in comparison with ideal weight)
and body mass index (BMI) were calculated for each
group. Weight loss at 3 years was expressed in absolute
terms and as a percent of excess weight loss (EWL). EWL
was calculated as weight at baseline   weight at 3 years ðÞ =
weight at baseline   ideal weight ðÞ . The ideal weight was
that associated with a BMI of 25 kg/m
2.
This study was conducted according to the guidelines
laid down in the Declaration of Helsinki. All participants
gave written consent before enrolling in the study, and
approval was obtained from the regional Ethics Committee
(Central Norway, Trondheim, Norway).
The surgical procedure consisted of creating a 20- to
30-ml gastric pouch along the lesser curvature of the
stomach. Division of the vagal nerve and its branches was
avoided. The jejunum was then advanced in an antecolic
position to create a 100–150-cm long alimentary limb,
which was anastomosed to the gastric pouch. All the
procedures were performed laparoscopically and by the
same team of surgeons.
The lifestyle intervention consisted of a “continuous
care” multidisciplinary program at Røros Rehabilitation
Centre (Norway), with intermittent stays at the center. The
program focused on physical activity, healthy eating, and
dynamic group-based psychotherapy [24].
Protocol
Participants arrived at the Research Center at St. Olav
Hospital in the morning after an overnight fast (at least
12 h) and were weighed without shoes and with light
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antecubital vein by a specialized nurse. Participants
ingested a chilled milkshake test meal (Fresubin® 2-kcal
drink (200 ml), 400 kcal, 15.6 g fat (35%), 45 g
carbohydrates (45%), and 20 g of protein (20%) from
Fresenius Kabi) within 10 min. Venous blood was drawn
from the cannula before the meal and at 30, 60, 90, and
120 min after meal consumption.
Hormone Measurement
Venous blood was collected into potassium/EDTA-coated
tubes containing 500 KIU aprotinin (Pentapharm, Basel,
Switzerland)/ml whole blood). Samples were then centri-
fuged at 2,000×g for 10 min and plasma kept at −80°C for
later analyses. Ghrelin and obestatin plasma levels were
determined by radioimmunoassay (ghrelin Total RIA Kit®,
Linco Research, St. Charles, MO, USA and obestatin
ultrasensitive RIA Kit®, Phoenix Pharmaceuticals, 330
Beach Road, Burlingame, CA, USA, respectively). The
sensitivity of the assays was of 93 pg/ml for ghrelin and
50 pg/ml for obestatin, with an inter-assay CV<10%. Due
to expected low concentrations of obestatin in these
samples, they were previously concentrated by freeze-
drying. The obestatin and ghrelin reagents are highly
specific without cross-reacting with other gastrointestinal
hormones. All samples were assayed in duplicate.
Statistical Analysis
Statistical analysis was carried out using SPSS 15.0 (SPSS
Inc., Chicago, IL). Data is reported as mean±SEM, and
statistical significance was assumed at P<0.05, unless
otherwise stated. Differences in the fasting plasma levels
of ghrelin and obestatin, and ghrelin/obestatin ration, were
assessed by one-way analysis of variance (ANOVA). The
effect of group and time on the plasma levels of ghrelin and
obestatin were assessed by a mixed between/within subjects
ANOVA and changes overtime within groups were
assessed by a repeated-measure ANOVA. The areas under
the curve (AUC) for ghrelin and obestatin plasma levels
were calculated from before to 120 min after breakfast,
using the trapezoidal rule. The effect of group on the AUC
for ghrelin and obestatin was assessed using one-way
ANOVA. The Bonferroni adjustment was applied in all
post hoc analysis (P<0.01 was used to account for the
possibility of an increased type 1 error). The magnitude of
suppression of ghrelin and obestatin was calculated, for
each participant, as peak (fasting plasma level) minus nadir
(lower value in the postprandial state) and expressed as a
percentage of baseline levels. Pearson correlations were
used to test the relationship between ghrelin plasma levels
and weight loss in groups (1) and (2).
Results
Characteristics of Study Groups
Table 1 shows the characteristics of each study group.
There were significant differences in age among groups
(P<0.05), however, post hoc comparisons revealed no
significant differences between specific groups, and no
significant correlations were observed between age and
fasting or AUC ghrelin or obestatin or ghrelin/obestatin
ratio. There were no significant differences in pre-
intervention excess weight or BMI between the three
groups. The RYGB group lost on average 34.0±20.8 kg
(P<0.001), while the lifestyle group lost 7.2±5.2 kg (P<
0.001), a difference that was statistically significant (P<
0.01). EWL (in percent) was also much larger in the RYGB
compared with the lifestyle group (P<0.0001). Post-
intervention BMI in the RYGB group was significantly
lower compared with the control group (P<0.05), but there
were no statistically significant differences between the
RYGB and lifestyle groups or between the lifestyle and
control groups.
Fasting Plasma Levels of Ghrelin and Obestatin
and Ghrelin/Obestatin Ratio
Fasting plasma levels of ghrelin and obestatin and ghrelin/
obestatin ratio in the different groups can be seen in
Table 2. There was a significant difference in fasting
ghrelin plasma levels among groups (P<0.01). Post hoc
comparisons indicated that fasting ghrelin plasma levels
were significantly elevated in the RYGB compared with the
pre-operative group (P=0.002), while there were no
significant differences between the lifestyle and control
groups or between the RYGB and the lifestyle groups.
There was also a significant difference in fasting
obestatin plasma levels among groups (P<0.01). Post hoc
comparisons revealed that, compared with the control
group, the RYGB group exhibited significantly higher
fasting obestatin plasma levels (P=0.002), while there were
no significant differences between the lifestyle and control
groups or between the RYGB and the lifestyle groups.
There was no statistically significant difference in
fasting ghrelin/obestatin ratio among the different study
groups (P>0.05).
Postprandial Plasma Levels of Ghrelin and Obestatin
Analysis of variance revealed a significant main effect of
time (P<0.0001) and group (P=0.045), but no time×group
interaction on ghrelin plasma levels (Fig. 1a). However,
post hoc comparisons indicated no significant differences in
postprandial ghrelin plasma levels overtime between the
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significant effect of time on ghrelin plasma levels was
observed in the RYGB (P<0.01) and control group (P=
0.022) and a tendency in the lifestyle group (P=0.058). The
area under the curve for ghrelin (0–120 min; pg/ml min
−1)
in the three study groups can be seen in Fig. 1b. ANOVA
showed no overall main effect of group (P>0.05). The
magnitude of suppression of total ghrelin in response to the
test meal was comparable in all groups at 28±18%, 22±
13%, and 23±9%, in the RYGB, lifestyle and control
groups, respectively (P>0.05).
A significant main effect of time (P<0.05) and group
(P<0.05) and a time×group interaction (P<0.05) was
observed on obestatin plasma levels (Fig. 2a). Post hoc
comparisons revealed no significant differences in obestatin
plasma levels overtime between groups, despite a tendency
for higher postprandial levels in the RYGB group compared
with the control group (P=0.021). When each group was
analyzed separately, no significant effect of time was
observed on obestatin plasma levels in any group. The area
under the curve for obestatin (0–120 min; pg/ml min
−1)i n
the three study groups can be seen in Fig. 2b. ANOVA
showed an overall main effect of group (P=0.012), and post
hoc analysis revealed that obestatin AUC was higher in the
RYGB group compared with the pre-operative control
group (P=0.01). The magnitude of suppression of obestatin
in response to the test meal was comparable in all groups at
33±13%, 25±22%, and 17±13%, in the RYGB, lifestyle,
and control groups (P>0.05).
Correlations between Weight Loss, Ghrelin and Obestatin
Plasma Levels, and Ghrelin/Obestatin Ratio
Correlations between weight loss at 3 years in the RYGB
and lifestyle groups and ghrelin, obestatin, and TG/
obestatin ratio were performed. Two outliers were identified
in the RYGB group (weight loss of 76 and 61.2 kg (3 and
2.2 SDs away from the mean, respectively)). No significant
correlations were observed between weight loss and ghrelin
or obestatin levels (fasting or AUC) or ghrelin/obestatin
ratio, either when all the patients’ data was used or after
removing the two outliers.
Discussion
In the present study, we found that fasting ghrelin and
obestatin plasma levels in weight-stable patients 3 years
after RYGB, but not after a lifestyle intervention, were
significantly higher compared with pre-operative morbid
obese patients (control group), despite no difference in
ghrelin/obestatin ratio among groups.
Ghrelin levels have been shown to be down-regulated in
obese individuals [25, 26] and to increase in response to
diet- and/or exercise-induced weight loss [2–4], suggesting
that ghrelin plays a role in the long-term regulation of
energy balance. An increase in ghrelin levels secondary to
weight loss can be seen as a compensatory mechanism to
try to restore energy balance by upregulating hunger levels
Table 2 Fasting plasma levels of ghrelin and obestatin and ghrelin/obestatin ratio in the different study groups
RYGB (n=9) Lifestyle (n=8) Control (n=9)
Ghrelin (pmol/L) 729±218* 632±99 449±114*
Obestatin (pg/ml) 102±37* 74±27 48±18*
Ghrelin/obestatin 7.4±1.2 9.2±2.9 10.4±4.7
Results are expressed as mean±SD
*P<0.01, with means sharing the same symbol denoting significant differences between groups
Table 1 Participant’s characteristics
RYGB (n=9) Lifestyle (n=8) Control (n=9)
Age (years) 42±10 51±7 38±8
Pre-intervention excess weight (kg) 62.4±19.8 54.1±14.7 58.4±12.4
Pre-intervention BMI (kg/m
2) 46.6±6.6 44.6±6.2 43.9±3.1
Post-intervention BMI (kg/m
2) 35.0±4.5* 42.1±7.0 43.9±3.1*
Weight loss at 3 years (kg) 34.0±20.8* 7.2±5.2* _
Excess weight loss (%) 51.9±17.4** 14.4±12.2** _
Results are expressed as mean±SD
*P<0.01, with means sharing the same symbol denoting significant differences between groups
**P<0.0001, with means sharing the same symbol denoting significant differences between groups
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after RYGB has been previously reported not to lead to a
compensatory increase in ghrelin concentrations [9, 10]o r
even to induce a reduction in its levels [5–8]. This was,
however, not supported by our results, which showed a
significant increase in fasting ghrelin plasma levels 3 years
after RYGB. It is important to acknowledge that the majority
of the previously published studies have focused on short-term
c h a n g e s( f r o m6w e e k st o1 2m o n t h s ) ,a n di ti sl i k e l yt h a t
ghrelin response after RYGB changes overtime.
It is well known that changes on the plasma levels of
ghrelin following bariatric surgery depend on the surgical
procedure. Gastric bypass surgery markedly suppresses
ghrelin concentrations while restrictive techniques such as
adjustable gastric banding lead to an increase [5]. These
differences in ghrelin response have been shown to be
independent of weight loss and a direct result of the degree
of functionality of the fundus [5, 27], the anatomical region
which has been shown to be the richest source of ghrelin
production in humans [28]. It is rather intriguing, therefore,
that despite bypassing most of the stomach and preventing
the fundus from contact with nutrients, circulating ghrelin
plasma levels were increased 3 years after RYGB in the
present study. It is possible that ghrelin-secreting cells in
the stomach increase the production of ghrelin as a counter-
regulatory mechanism to the long-term absence of contact
with nutrients as a result of RYGB. Another possibility is
that the increase in ghrelin levels reflects an increased
secretion from ghrelin-secreting cells outside of the
stomach, since it is known that other organs, including the
duodenum, the jejunum, and the lung can secret ghrelin
[29]. However, the exact cause for the increased ghrelin
levels after long-term sustained weight loss following
RYGB remains a matter of continued discussion, and more
studies are needed in this area. The only available study
Fig. 1 a Ghrelin plasma levels (picograms per milliliter) over time after
breakfast in pre-operative morbid obese patients (n=9; open diamonds)
and patients 3 years after RYGB (n=9; closed squares) or a lifestyle
intervention (n=8; closed triangles). Values represent means±SEM.
Repeated-measures ANOVA showed a significant effect of time (P<
0.0001) and group (P=0.045), but no interaction. b Area under the
curve for ghrelin (0–120 min) (picograms per milliliter per minute) in
pre-operative morbidly obese patients (hatched bar) and patients 3 years
after RYGB (solid bar) or a lifestyle intervention (open bar). ANOVA
showed no overall main effect of group (P>0.05)
Fig. 2 a Obestatin plasma levels (picograms per milliliter) over time
after breakfast in pre-operative morbid obese patients (n=9; open
diamonds) and patients three years after RYGB (n=9; closed squares)
or a lifestyle intervention (n=8; closed triangles). Values represent
means±SEM. Repeated-measures ANOVA showed a significant effect
of time (P<0.05) and group (P<0.05) and a time×group interaction
(P<0.01). b Area under the curve for obestatin (0–120 min; picograms
per milliliter per minute) in pre-operative morbidly obese patients
(hatched bar) and patients 3 years after RYGB (solid bar)o ra
lifestyle intervention (open bar). ANOVA showed an overall main
effect of group on obestatin AUC (P=0.007). Asterisk reveals
significant differences between groups (P=0.01)
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reported no difference in the fasting plasma levels of either
total ghrelin or its active component (acylated ghrelin)
between weight-stable patients after RYGB and BMI- and
age-matched controls [28]. However, that study suffers
from several drawbacks since there was no pre-operative
control group and the time after RYGB was very
heterogeneous (15–71 months) [28]. Differences in surgical
techniques (such as size of the pouch and integrity of the
remaining fundus), follow-up periods, and magnitude of
weight loss, as well as the status of energy balance are
likely to contribute to some of the inconsistencies reported
above. Although a reduction in ghrelin levels shortly after
RYGB can contribute to weight reduction, the present study
seems to suggest that ghrelin is unlikely to be a mediator in
long-term weight loss maintenance after RYGB, particularly
because we found no correlation between ghrelin levels at
3 years and weight loss.
Fasting ghrelin plasma levels in the lifestyle group, on the
other hand, were not significantly different from the pre-
operative control group. Three potential explanations can be
provided for this finding. First, it is possible that the weight
reduction was not large enough to have produced a significant
increase in ghrelin plasma levels. Second, it is possible that
ghrelin levels had previously been increased but that they
returned to baseline levels afterwards, since at least two
studies have shown that ghrelin plasma levels return to
baseline with sustained weightlossmaintenance after lifestyle
interventions [30, 31]. Finally, despite a significant weight
loss, BMI at 3 years in the lifestyle group was not
significantly different from the BMI of the control group.
Ghrelin also seems to reflect acute feeding state in
humans, since its concentrations increase with fasting and
quickly decline after a meal [29] and have been associated
with pre-meal hunger and meal initiation [32]. The
postprandial suppression of ghrelin seen postprandially in
normal-weight individuals [2] has been found to be blunted
after RYGB in some studies [2, 6, 9, 33] while exaggerated
in others [34]. In the present study, ghrelin plasma levels
decreased postprandially in all groups, with no significant
differences in postprandial plasma levels or the magnitude
of maximal suppression among them.
We have also reported in the present study that weight loss
maintenance 3 years after RYGB, but not after a lifestyle
intervention, was associated with a significant increase in
fasting obestatin plasma levels, compared with pre-operative
morbid obese patients. Moreover, no differences were
observed in ghrelin/obestatin ratio among groups. These
results are extremely exciting since the only previously
published study in this area reported no change in fasting
obestatin plasma levels 2 years after RYGB and a significant
reduction in ghrelin/obestatin ratio [8]. Regarding lifestyle
interventions, studies in children have reported increased
obestatin plasma levels [22, 23] and ghrelin/obestatin ratio
[22] after weight reduction achieved through diet and
physical activity. However, studies in adults, and particularly
in the morbidly obese population, are missing. The same
potential reasons highlighted before for the absence of a
significant difference in ghrelin levels between the lifestyle
and the control group could also apply here for obestatin.
More studies are needed to clarify the impact of weight loss
and weight loss maintenance achieved through different
methods on obestatin plasma levels.
The postprandial profile of obestatin remains also contro-
versial.Mostofthe studiesshowthatobestatinlevelsdecrease
in the postprandial period in both normal-weight [18, 20, 35]
and borderline obese individuals [20]; however, one study
reported no change in obestatin plasma levels after a mixed
meal in normal-weight and morbidly obese subjects [19]. We
were the first to look at the impact of weight loss achieved
by RYGB or lifestyle intervention on the postprandial release
of obestatin. We have shown no significant change in
obestatin plasma levels overtime after a liquid balanced
meal in neither morbid obese patients (controls) nor weight-
stable patients 3 years after RYGB or a lifestyle intervention.
However, postprandial obestatin levels were significantly
higher in the RYGB group compared with the pre-operative
control group. It is difficult to speculate on the implications
of our findings, since, as highlighted by a recent review, the
role of obestatin on energy balance remains controversial
[36]. More studies are urgently needed to elucidate the role
of obestatin on energy homeostasis.
This study has a few potential limitations. First, it has a
cross-sectional design and a low sample size. We acknowl-
edge that this study might not have adequate statistical power
and, therefore, should be performed in larger cohorts before
strong conclusions can be drawn regarding their clinical
relevance. Moreover, more longitudinal studies need to be
done to unveil the physiological mechanisms mediating long-
termweight lossafter RYGBandlifestyle interventionsinthis
group of patients. Second, we measured total ghrelin and not
acylated ghrelin, which is thought to be essential for its
biological activities. Although total ghrelin has been shown to
correlate well with acylated ghrelin [37], the two forms may
be differentially regulated in altered nutritional states and
pre- and post-gastric surgery, and therefore we cannot
exclude the possibility that acylated ghrelin may have
responded differently and shown a different relationship
with obestatin. Third, there was an overall difference in age
among groups. However, post hoc comparisons revealed no
significant differences between specific groups, and no
significant correlations were observed between age and
fasting or AUC ghrelin or obestatin or ghrelin/obestatin
ratio, making it unlikely for age differences to have had a
significant impact on our results. Despite these limitations,
we would like to emphasize that this study is strengthened by
756 OBES SURG (2011) 21:751–758the existence of a pre-operative control group, the fact that
patients were weight-stable and the long follow-up period.
In conclusion, the results of this study suggest that
weight loss maintenance after RYGB is associated with a
significant increase in fasting ghrelin and obestatin plasma
levels, but no change in ghrelin/obestatin ratio, compared
with pre-operative morbidly obese patients (controls). On
the other hand, weight loss (maintenance) after a lifestyle
intervention was not associated with a significant increase
in fasting ghrelin or obestatin levels, although this was
likely to have been caused by the much lower magnitude of
weight loss (7 vs. 34 kg). Ghrelin is, therefore, unlikely to
contribute to long-term weight loss maintenance after
RYGB and other factors are likely to be involved.
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